Therefore, targeting the HIC1-p53 axis therapeutically, through approaches like demethylating agents or Δ133p53 inhibitors, may help enhance response to chemotherapy in Ov-CCA patients. The gene discussed is TP53; the disease is cholangiocarcinoma.